Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
about
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyLung cancer in the era of precision medicineMutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Alectinib for treatment of ALK-positive non-small-cell lung cancer.
P2860
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@ast
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@en
type
label
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@ast
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@en
prefLabel
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@ast
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@en
P2860
P1476
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
@en
P2860
P304
P356
10.1158/1078-0432.CCR-14-2306
P407
P577
2014-09-16T00:00:00Z